<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02568644</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE 21057913.9.0000.5135</org_study_id>
    <nct_id>NCT02568644</nct_id>
  </id_info>
  <brief_title>Ginger Capsules for the Acute Treatment of Migraine Attacks</brief_title>
  <official_title>Double-blind Placebo-controlled Clinical Trial of Ginger (Zingiber Officinale) Addition to Ketoprofen for the Acute Treatment of Migraine Attacks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Minas Gerais</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of Minas Gerais</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study was to evaluate ginger efficacy as an adjuvant to ketoprofen
      for the treatment of headache and other symptoms related with migraine attacks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with the diagnosis of migraine according to the IHS criteria were enrolled in the
      study during a migraine attack. Patients received two 200 mg capsules of dry ginger extract
      (5% active ingredient) or two capsules of placebo (cellulose) in addition to an intravenous
      dose of ketoprofen (100 mg) to treat the migraine attack.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in headache severity.</measure>
    <time_frame>2 hours</time_frame>
    <description>The severity of headache was assessed with four-point scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in headache severity.</measure>
    <time_frame>2 hours</time_frame>
    <description>The severity of headache was assessed with visual numeric scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in headache severity.</measure>
    <time_frame>2 hours</time_frame>
    <description>The severity of headache was assessed with faces pain scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum levels of biomarkers.</measure>
    <time_frame>2 hours</time_frame>
    <description>Evaluated biomarkers: neurotrophic factors and inflammatory mediators.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Extract of ginger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerois) and intravenous ketoprofen (100mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose) and intravenous ketoprofen (100mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Extract of ginger</intervention_name>
    <description>People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerois).</description>
    <arm_group_label>Extract of ginger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cellulose</intervention_name>
    <description>People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose).</description>
    <arm_group_label>Cellulose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous ketoprofen</intervention_name>
    <description>People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).</description>
    <arm_group_label>Extract of ginger</arm_group_label>
    <arm_group_label>Cellulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

               -  Migraine diagnosis for at least one year;

               -  One to six migraine attacks per month.

          -  Exclusion Criteria:

               -  Patients with headaches not characterized as migraine;

               -  Pregnant or lactating women;

               -  Fertile and sexually active women who do not use contraception;

               -  Abuse of painkillers, alcohol or drugs;

               -  People with hypersensitivity to ginger;

               -  People with other neurological diseases;

               -  People in use of anticoagulant drugs;

               -  People who have started the disease after 50 years old.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adaliene VM Ferreira, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Federal University of Minas Gerais</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laís B Martins, Ma</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Minas Gerais</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antônio L Teixeira, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Minas Gerais</affiliation>
  </overall_official>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2015</study_first_posted>
  <last_update_submitted>October 2, 2015</last_update_submitted>
  <last_update_submitted_qc>October 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Minas Gerais</investigator_affiliation>
    <investigator_full_name>Antonio L Teixeira Jr</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Ginger</keyword>
  <keyword>Acute treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

